196 related articles for article (PubMed ID: 28526140)
1. Thymic malignancies: Twisting between autoimmunity and immunotherapy.
Girard N
Lung Cancer; 2017 Aug; 110():68-70. PubMed ID: 28526140
[No Abstract] [Full Text] [Related]
2. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
3. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J
Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004
[TBL] [Abstract][Full Text] [Related]
4. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
5. Heather Wakelee on the Role of Checkpoint Inhibitors in Advanced Lung Cancer.
Wakelee H
Oncology (Williston Park); 2017 Jun; 31(6):440, 442. PubMed ID: 28620899
[No Abstract] [Full Text] [Related]
6. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.
Necchi A; Raggi D; Giannatempo P; Sonpavde G; Galsky MD; Bellmunt J; Mariani L; Miceli R
Clin Genitourin Cancer; 2017 Oct; 15(5):509-512.e9. PubMed ID: 28478885
[No Abstract] [Full Text] [Related]
7. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
8. Thymoma and autoimmunity.
Shelly S; Agmon-Levin N; Altman A; Shoenfeld Y
Cell Mol Immunol; 2011 May; 8(3):199-202. PubMed ID: 21317916
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Caux C; Bay JO
Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
[TBL] [Abstract][Full Text] [Related]
10. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
Galsky MD
Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
[No Abstract] [Full Text] [Related]
11. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
Ullén A
Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
[No Abstract] [Full Text] [Related]
12. Checkpoint inhibitors: outstanding efficacy but at what cost?
Klastersky JA
Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
[No Abstract] [Full Text] [Related]
13. Mutation Ensemble for Response to Programmed Cell Death 1 Inhibition in Thymic Carcinoma.
Lee HS; Truong CY; Burt BM
J Thorac Oncol; 2018 Aug; 13(8):e150-e152. PubMed ID: 30049379
[No Abstract] [Full Text] [Related]
14. Preface: More than two decades of modern tumor immunology.
Galluzzi L; Rudqvist NP
Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
[No Abstract] [Full Text] [Related]
15. Immunotherapy in Lung Cancer.
Du L; Herbst RS; Morgensztern D
Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for head and neck cancers: an update and future perspectives.
Doescher J; Laban S; Schuler PJ; Brunner C; Hoffmann TK
Immunotherapy; 2019 May; 11(7):561-564. PubMed ID: 30943860
[No Abstract] [Full Text] [Related]
17. Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer.
McArthur H
Oncology (Williston Park); 2019 Apr; 33(4):137-40. PubMed ID: 30990566
[No Abstract] [Full Text] [Related]
18. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor.
Quresh Q; Quinet R
J Clin Rheumatol; 2017 Jun; 23(4):235. PubMed ID: 28538282
[No Abstract] [Full Text] [Related]
20. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Bellmunt J; Powles T; Vogelzang NJ
Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
